|
|
|
|
Hello Everyone!
We hope you are all enjoying a wonderful Summer! While there are definitely "Summer Vacation" vibes floating around, IAS still hard at work developing programs, doing important research, and reaching our communities. It's nice to feel a sense of traditional summer hustle and bustle again with summer travels, outdoor activities, and fun in the sun.
This month, we would like to spotlight a program that meshes all of these things - summer travel fun and addiction medicine research - together perfectly - the 2022 Maymester lead by IAS Associate Director of Education, Dr. Terry Church from USC School of Pharmacy. Students joined Dr. Church on a 21-day immersive course to Bulgaria, Greece, Romania and Turkey where they explored Balkan History, Geography, and Folk Medicines.
This course, RXRS499 offered an immersive experience where students had the opportunity to learn about Folk Medicine and Practices in the Balkans, explored the benefits and consequences of Folk Medicine as well as its role as a cultural and political tool. Congrats to Dr. Church on this successful and memorable trip! For more information on the Maymester program please click here.
While Dr. Church was abroad, a little closer to home, on May 26th, IAS Director, Dr. Adam Leventhal participated in a panel discussion at the LA Bioscience Ecosystem Summit (LABEST) discussing the Strategic Priorities and Opportunities in Neuropsych Disorders of the California Institute for Regenerative Medicine (CIRM). For a snippet of this panel discussion, click here. Events like these are ways in which IAS continues to reach community members and support community engagement by providing expertise in science and research.
Speaking of supporting the community, IAS faculty members Jessica Barrington-Trimis, PhD and Alayna Tackett, PhD also gave talks at a symposium hosted by CHLA which was aimed at "Addressing the Youth Vaping Epidemic". This 3-day event on May 31-June 2 was an effort to educate and provide tools for working with youth and young adults with regard to the vaping epidemic. Thank you Drs. Barrington-Trimis and Tackett for not only continuing building awareness of e-cigarettes and their impact on the pediatric population but also providing education and advocacy resources to medical professionals.
We are looking forward to resuming the 2022 IAS Distinguished Speaker Series next month on August 24th when we welcome Morgan Philbin, PhD, MHS, from Columbia University's Mailman School of Public Health. Dr. Philbin will be talking about "Cannabis policy implementation and outcomes among minoritized youth and young adults in the United States: A mixed methods analysis". Please see below for more information about the talk and to register for the event! Lunch and parking will be provided. We hope to see you there!
As always, we are very appreciative of your continued support of the Institute for Addiction Science and look forward to continuing to share our ongoing and upcoming projects and activities with you.
Warmest Regards,
Adam Leventhal, John Clapp, Daryl Davies, Ricky Bluthenthal, Terry Church, Vickie Williams and Loba Ojo
|
|
|
UPCOMING EVENTS AND MEETINGS
|
|
|
This talk will be in-person at the Soto Street Building, Room 116
1845 N. Soto Street
Los Angeles, CA 90032
Upon arrival, please see the receptionist and obtain a parking permit to place on your dashboard. Lunch will be served outside in the courtyard immediately following the talk.
Virtual option also available.
CLICK HERE TO REGISTER
|
|
As a reminder, IAS is requesting project ideas from any IAS participating faculty members to award seed funding that will lead to high impact transdisciplinary projects. Projects that will advance any of IAS’s three missions—research, education, and community engagement and service—are encouraged. These project pitches will require a brief one-page description and budget and should propose work that can be completed within 1-year, but serve as the basis for a longer-term initiative, as described here.
|
|
|
IAS MEMBER RESEARCH CORNER
|
|
|
|
Below are selected publications from the previous month (June 2022) from faculty members and scholars of the Institute for Addiction Science.
Blanchette, J. G., Pacula, R. L., Smart, R., Lira, M. C., Boustead, A. E., Caulkins, J. P., Kilmer, B., Kerr, W. C., Treffers, R., & Naimi, T. S. (2022). Rating the comparative efficacy of state-level cannabis policies on recreational cannabis markets in the United States. International Journal of Drug Policy, 106, 103744. https://doi.org/10.1016/j.drugpo.2022.103744
Breland, A. B., Carroll, D., Denlinger-Apte, R., Ross, J. C., Soto, C., White, C., Donny, E. C., Fagan, P., Gardiner, P., Eissenberg, T., & Guy, M. C. (2022). Centering Racial Justice for Black/African American and Indigenous American people in Commercial Tobacco Product Regulation. Preventive Medicine, 107117. https://doi.org/10.1016/j.ypmed.2022.107117
Chen-Sankey, J., Jeong, M., Wackowski, O. A., Unger, J. B., Niederdeppe, J., Bernat, E., Bansal-Travers, M., Moran, M., Kennedy, R. D., Broun, A., Hacker, K., & Choi, K. (2022). Noticing people, discounts and non-tobacco flavours in e-cigarette ads may increase e-cigarette product appeal among non-tobacco-using young adults. Tobacco Control. https://doi.org/10.1136/tobaccocontrol-2022-057269
Feder, K. A., Choi, J. C., Schluth, C., Hayashi, K., DeBeck, K., Milloy, M.-J., Kirk, G., Mehta, S. H., Kipke, M., Moore, R. D., Baum, M. K., Shoptaw, S., Gorbach, P. M., Mustanski, B., Javanbakht, M., Siminski, S., & Genberg, B. L. (2022).Factors associated with self-reported avoidance of harm reduction services during the COVID-19 pandemic by people who use drugs in five cities in the United States and Canada. Drug and Alcohol Dependence, 109544. https://doi.org/10.1016/j.drugalcdep.2022.109544
Goodsmith, N., Cohen, A. N., Pedersen, E. R., Evans, E., Young, A. S., & Hamilton, A. B. (2022). Predictors of functioning and recovery among men and women veterans with schizophrenia. Community Mental Health Journal. https://doi.org/10.1007/s10597-022-00979-x
Hammond, D., Goodman, S., Wadsworth, E., Freeman, T. P., Kilmer, B., Schauer, G., Pacula, R. L., & Hall, W. (2022). Trends in the use of cannabis products in Canada and the USA, 2018 – 2020: Findings from the International Cannabis Policy Study. International Journal of Drug Policy, 105, 103716. https://doi.org/10.1016/j.drugpo.2022.103716
Lapham, G. T., Matson, T. E., Carrell, D. S., Bobb, J. F., Luce, C., Oliver, M. M., Ghitza, U. E., Hsu, C., Browne, K. C., Binswanger, I. A., Campbell, C. I., Saxon, A. J., Vandrey, R., Schauer, G. L., Pacula, R. L., Horberg, M. A., Bailey, S. R., McClure, E. A., & Bradley, K. A. (2022). Comparison of medical cannabis use reported on a confidential survey vs documented in the electronic health record among primary care patients. JAMA Network Open, 5(5). https://doi.org/10.1001/jamanetworkopen.2022.11677
Mason, T. B., Martinez, C., Dunton, G. F., Belcher, B. R., & Pang, R. D. (2022). Understanding daily life experiences of women who smoke: The role of smoking-related weight control expectancies. Addictive Behaviors, 134, 107413. https://doi.org/10.1016/j.addbeh.2022.107413
Mattingly, D. T., Howard, L. C., Krueger, E. A., Fleischer, N. L., Hughes-Halbert, C., & Leventhal, A. M. (2022). Change in distress about police brutality and substance use among young people, 2017–2020. Drug and Alcohol Dependence, 237, 109530. https://doi.org/10.1016/j.drugalcdep.2022.109530
Netherland, J., Kral, A. H., Ompad, D. C., Davis, C. S., Bluthenthal, R. N., Dasgupta, N., Gilbert, M., Morgan, R., & Wheelock, H. (2022). Principles and metrics for evaluating Oregon’s innovative drug decriminalization measure. Journal of Urban Health, 99(2), 328–331. https://doi.org/10.1007/s11524-022-00606-w
Odegard, M. N., Ourshalimian, S., Hijaz, D., Chen, S. Y., Kim, E., Illingworth, K., & Kelley-Quon, L. I. (2022). Factors associated with safe prescription opioid disposal after surgery in adolescents. Journal of Surgical Research, 279, 42–51. https://doi.org/10.1016/j.jss.2022.05.023
Pedersen, E. R., Hummer, J. F., Davis, J. P., Fitzke, R. E., Christie, N. C., Witkiewitz, K., & Clapp, J. D. (2022). A mobile-based pregaming drinking prevention intervention for college students: Study protocol for a randomized controlled trial. Addiction Science & Clinical Practice, 17(1). https://doi.org/10.1186/s13722-022-00314-5
Semborski, S., Henwood, B., Madden, D., & Rhoades, H. (2022). Health care needs of young adults who have experienced homelessness. Medical Care, Publish Ahead of Print. https://doi.org/10.1097/mlr.0000000000001741
Sussman, S., Galimov, A., Meza, L., Huh, J., Baezconde-Garbanati, L., & Pokhrel, P. (2021). Peer crowd identification of young and early middle adulthood customers at Vape Shops. Journal of Drug Education, 50(3-4), 98–107. https://doi.org/10.1177/00472379221106365
Tran, D. D., Oh, H., Zhou, S., & Pedersen, E. R. (2022). Depression and perceptions of social norms and harms for electronic and combustible cigarette use: Associations with tobacco use in college students. Psychiatry Research Communications, 2(3), 100053. https://doi.org/10.1016/j.psycom.2022.100053
Tucker, J. S., Dunbar, M. S., Perez, L. G., Seelam, R., Troxel, W. M., Davis, J. P., & D’Amico, E. J. (2022). Young adults’ perceived impact of covid-19 pandemic on sleep and other functioning: Does it differ for sexual/gender and racial/ethnic minorities? Behavioral Sleep Medicine, 20(3), 294–303. https://doi.org/10.1080/15402002.2022.2075366
Wenger, L. D., Doe-Simkins, M., Wheeler, E., Ongais, L., Morris, T., Bluthenthal, R. N., Kral, A. H., & Lambdin, B. H. (2022). Best practices for community-based overdose education and naloxone distribution programs: Results from using the delphi approach. Harm Reduction Journal, 19(1). https://doi.org/10.1186/s12954-022-00639-z
|
|
|
ADDICTION SCIENCE IN THE NEWS
|
|
|
This section highlights a few news articles from the month highlighting research or programming from an IAS member or IAS research program, as well as articles related to addiction science.
From the Bones of Victims, a Doctor Unearths a Drug War's True Toll
The New York Times, June 3rd, 2022
A Harrowing Journey From Cornell to Addiction to Prison
The New York Times, June 7th, 2022
Failures in the generic drug market cost patients millions
USC News, June 9th, 2022
Experts say we have the tools to fight addiction. So why are more Americans overdosing than ever?
The New York Times, June 24th, 2022
A Psychedelic Renaissance at the V.A.
The New York Times, June 24th, 2022
Fentanyl Use is Empowering?
The Wall Street Journal, June 29th, 2022
|
|
|
Research Team - Department of Population and Public Health Sciences
The Department of Population and Public Health Sciences is in search of: A dependable, flexible, and detail-oriented person is needed to join a research team at the University of Southern California to participate in new pilot studies related to substance use, including studies related to cannabis use during pregnancy. These studies are investigating harm reduction approaches to substance use, including how expanding cannabis legalization may worsen existing maternal health disparities.
Employment Involves:
(1) Data collection. Conducting one-on-one interviews and focus groups with study participants (e.g., people who inject drugs, women who use cannabis during pregnancy, young women who vape, health providers and midwives);
(2) Data analysis. Conducting data analysis (e.g., thematic analysis, grounded theory using ATLAS.ti);
(3) Project management. Supporting all study-related project and data management (e.g., Institutional Review Board submissions and related protocols, managing and storing data according to HIPAA, managing
transcription of data).
Excellent English writing and speaking skills are required, and bilingual in English and Spanish writing and speaking skills are ideal. The ideal candidate will have strong organizational capabilities, superb problem-solving skills, and a demonstrated ability to work independently while managing multiple tasks. Opportunities for mentorship and support in writing manuscript writing and peer-reviewed publications are available. Flexible hours on some evenings and weekends may be needed (e.g., conducting research interviews to accommodate study participants’ schedules). The majority of the work will be conducted remote from 9am-5pm Monday through Friday). Prior experience in a research environment is preferred.Bachelor’s or Master’s degree in the social sciences or in a health related field is preferred.
For more information or to apply, please email Rachel Carmen Ceasar, PhD, Assistant Professor of Population and Public Health Sciences at rceasar@usc.edu.
|
|
Minor in Addiction Science - Registration is Open!
This minor is designed for students with an interest in addiction who plan to enter medical, pharmaceutical, social work, or other graduate programs, or who are interested in pursuing a career in which a background in addiction may prove beneficial.
Courses and research are delivered from broad areas of expertise within - Preventive Medicine, Pharmacy, Social Work, and Psychology. Students will gain a real-world understanding and recognize that addictive behaviors exist within a complex environment involving commercial - economic, political, and sociocultural forces.
|
|
| Title |
Release Date |
Code |
Issuing Org |
FOA/Notice # |
| Transformative Research on the Basic Mechanisms of Polysubstance use in Addiction (R01 - Clinical Trial Not Allowed) |
6/2/2022 |
R01 |
NIDA |
RFA-DA-23-015 |
| Stimulants and HIV: Addressing Contemporary and Recurring Epidemics (R61/R33 - Clinical Trial Required) |
5/16/2022 |
R61/R33 |
NIDA |
RFA-DA-23-008 |
| Behavioral and Integrative Treatment Development Program (R01 Clinical Trial Optional) |
5/9/2022 |
R01 |
NIDA |
PAR-22-182 |
| National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of Mental Disorders or Alcohol Use Disorder (U01 Clinical Trial Optional) |
5/6/2022 |
U01 |
NIMH |
PAR-22-143 |
| Specialized Alcohol Research Centers (P50 Clinical trial Optional) |
4/14/2022 |
P50 |
NIAAA |
RFA-AA-22-001 |
| Comprehensive Alcohol Research Centers (P60 Clinical trial Optional) |
4/14/2022 |
P60 |
NIAAA |
RFA-AA-22-002 |
| Alcohol Health Services Research (R01 Clinical Trial Optional) |
4/7/2022 |
R01 |
NIAAA |
PAR-22-156 |
| Alcohol Treatment and Recovery Research (R01 Clinical Trial Required) |
4/7/2022 |
R01 |
NIAAA |
PAR-22-158 |
| Increasing Immediate Engagement and Retention in HIV Treatment with Substance Users (R01- Clinical Trials Required) |
4/6/2022 |
R01 |
NIDA |
RFA-DA-23-002 |
| Enhancing HIV Reservoir Susceptibility to Elimination (R01 Clinical Trial Not Allowed) |
3/29/2022 |
R01 |
NIAID |
RFA-AI-22-025 |
| Single Cell Opioid Responses in the Context of HIV (SCORCH) Program Expansion: CNS Data Generation for Chronic Opioid, Methamphetamine, Cocaine and/or Cannabinoid Exposures (U01 - Clinical Trial Not Allowed) |
3/15/2022 |
U01 |
NIDA |
RFA-DA-23-004 |
| NIDA Research Center of Excellence Grant Program (P50 Clinical Trial Optional) |
3/14/2022 |
P50 |
NIDA |
PAR-22-133 |
| Enhancing Social Connectedness and Ameliorating Loneliness to Prevent and Treat SUD and Support Recovery (R21 - Clinical Trial Not Allowed) |
3/14/2022 |
R21 |
NIDA |
RFA-DA-23-009 |
| Tobacco Centers of Regulatory Science (TCORS) for Research Relevant to the Family Smoking Prevention and Tobacco Control Act (U54 Clinical Trial Optional) |
3/7/2022 |
U54 |
ODP |
RFA-OD-22-004 |
| Center for Coordination of Analysis, Science, Enhancement, and Logistics (CASEL) in Tobacco Regulatory Science (U54 Clinical Trial Not Allowed) |
3/7/2022 |
U54 |
ODP |
RFA-OD-22-003 |
| Implementing Comprehensive HIV services in Syringe Service Program (SSP) Settings (R01 - Clinical Trial Required) |
2/25/2022 |
R01 |
NIDA |
RFA-DA-23-006 |
| Investigational New Drug (IND)-enabling and Early-Stage Development of Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ Damage (U43/U44 Clinical Trial Optional) |
1/21/2022 |
U43/U44 |
NIAAA |
PAR-22-102 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R21 Clinical Trial Optional) |
1/10/2022 |
R21 |
NIDA |
RFA-DA-22-038 |
| Accelerating the Pace of Drug Abuse Research Using Existing Data (R01 Clinical Trial Optional) |
1/10/2022 |
R01 |
NIDA |
RFA-DA-22-037 |
| Opportunities for Collaborative Research at the NIH Clinical Center (U01 Clinical Trial Optional) |
11/19/2021 |
U01 |
NICHD |
PAR-21-343 |
| Interventions for Stigma Reduction to Improve HIV/AIDS Prevention, Treatment and Care in Low- and Middle- Income Countries (R01 - Clinical Trial Optional) |
9/28/2021 |
R01 |
FIC |
PAR-21-344 |
| High Priority HIV and Substance Use Research (R01 Clinical Trial Optional) |
9/8/2021 |
R01 |
NIDA |
RFA-DA-22-040 |
| Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional) |
9/2/2021 |
R21 |
NIDA |
PAR-22-027 |
| NIDA Research Education Program for Clinical Researchers and Clinicians (R25 Clinical Trial Not Allowed) |
9/1/2021 |
R25 |
NIDA |
PAR-21-320 |
| Exploiting in Vivo or in Situ Imaging Approaches to Understand HIV-relevant Processes In The Context of Substance Use Disorders (R61/R33 Clinical Trials Optional) |
7/8/2021 |
R61/R33 |
NIDA |
RFA-DA-23-001 |
| Mechanisms of Alcohol Tolerance (R21/R33 Clinical Trial Optional) |
6/22/2021 |
R21/R33 |
NIAAA |
PAR-21-250 |
| Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) |
5/19/2021 |
R15 |
NIGMS |
PAR-21-155 |
| Academic Research Enhancement Award for Undergraduate-Focused Institutions (R15 Clinical Trial Required) |
5/19/2021 |
R15 |
NIDA |
PAR-21-154 |
| Summer Research Education Experience Program (R25 Clinical Trial Not Allowed) |
5/10/2021 |
R25 |
NINDS |
PAR-21-168 |
| BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed) |
4/27/2021 |
R01 |
NIMH |
RFA-MH-21-175 |
| Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (U44 Clinical Trial Optional) |
4/23/2021 |
U44 |
NINDS |
PAR-21-233 |
| Cutting-Edge Basic Research Awards (CEBRA) (R21 Clinical Trial Optional) |
3/26/2021 |
R21 |
NIDA |
PAR-21-208 |
| Secondary Analyses of Existing Datasets of Tobacco Use and Health (R21 Clinical Trial Not Allowed) |
3/10/2021 |
R21 |
NIH |
RFA-OD-21-003 |
| Advancing technologies to improve delivery of pharmacological, gene editing, and other cargoes for HIV and SUD mechanistic or therapeutic research (R01- Clinical Trial Optional) |
2/26/2021 |
R01 |
NIDA |
RFA-DA-22-010 |
| Tobacco Regulatory Science (R01 Clinical Trial Optional) |
2/17/2021 |
R01 |
NIH |
RFA-OD-21-002 |
| Exploratory studies to investigate mechanisms of HIV infection, replication, latency, and/or pathogenesis in the context of substance use disorders (R61/R33 - Clinical Trial Not Allowed) |
2/2/2021 |
R61/R33 |
NIDA |
RFA-DA-22-004 |
| Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional) |
12/11/2020 |
R61/R33 |
NIAAA |
PAR-21-098 |
| Providing Research Education Experiences to Enhance Diversity in the Next Generation of Substance Use and Addiction Scientists (R25 Clinical Trials Not Allowed) |
10/28/2020 |
R25 |
NIDA |
PAR-20-236 |
| Discovery of Cell-based Chemical Probes for Novel Brain Targets (R21 Clinical Trial Not Allowed) |
10/14/2020 |
R21 |
NIMH |
PAR-21-028 |
| Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) |
10/14/2020 |
R01 |
NIMH |
PAR-21-029 |
| Health Services Research on Minority Health and Health Disparities (R01- Clinical Trial Optional) |
9/30/2020 |
R01 |
NIMHD |
PAR-20-310 |
| New Models of Integrated HIV/AIDS, Addiction, and Primary Care Services (R01 Clinical Trial Required) |
8/28/2020 |
R01 |
NIDA |
PAR-20-273 |
| Mentored Career Development Program (K01) for Early Stage Investigators Using Nonhuman Primate Research Models (K01 Independent Clinical Trial Not Allowed) |
8/24/2020 |
K01 |
NIAID |
PAR-20-258 |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) |
8/17/2020 |
R01 |
NIDA |
PAR-20-238 |
| Research to Improve Native American Health (R21 Clinical Trials Optional) |
8/17/2020 |
R21 |
NIDA |
PAR-20-214 |
| BRAIN Initiative: Data Archives for the BRAIN Initiative (R24 Clinical Trial Optional) |
8/7/2020 |
R24 |
NIMH |
RFA-MH-20-600 |
| NIDA Core "Center of Excellence" Grant Program (P30 Clinical Trial Optional) |
7/17/2020 |
P30 |
NIDA |
PAR-20-267 |
| BRAIN Initiative: Tools for Germline Gene Editing in Marmosets (U01 - Clinical Trial Not Allowed) |
7/17/2020 |
U01 |
NIDA |
RFA-DA-21-006 |
| Promoting Research on Music and Health: Phased Innovation Award for Music Interventions (R61/R33 Clinical Trial Optional) |
7/15/2020 |
R61/R33 |
NCCIH |
PAR-20-266 |
| Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects (R21 Clinical Trial Not Allowed) |
7/7/2020 |
R21 |
NINDS |
PAR-20-253 |
| NIDA Mentored Clinical Scientist Development Program Award in Substance Use and Substance Use Disorder Research (K12 Clinical Trial Optional) |
7/1/2020 |
K12 |
NIDA |
PAR-20-249 |
| Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R21- Clinical Trial Not Allowed) |
3/25/2020 |
R21 |
NIDA |
PAR-20-148 |
| Extracellular RNA carrier subclasses in processes relevant to Substance Use Disorders or HIV infection (R01- Clinical Trial Not Allowed) |
3/25/2020 |
R01 |
NIDA |
PAR-20-147 |
| Integrative Research on Polysubstance Abuse and Disorder (R61/R33 Clinical Trial Optional) |
10/18/2019 |
R61/R33 |
NIDA |
PAR-20-035 |
| Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01-Clinical Trial Optional) |
7/25/2019 |
R01 |
NIDA |
PAR-19-318 |
| Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) |
5/15/2019 |
R61/R33 |
NIDA |
PAR-19-282 |
| Alcohol and Other Substance Use Research Education Programs for Health Professionals (R25 Clinical Trial Not Allowed) |
3/4/2019 |
R25 |
NIAAA |
PAR-19-207 |
|
|
|
|
|
|
|
|
